VeinWay

VeinWay Overview

VeinWay is focused on developing a novel technology for crossing chronically occluded veins. VeinWay's Traversa delivers the first dedicated device designed for venous recanalization that will improve outcomes and allow physicians to reliably, safely and easily complete endovascular procedures in a timely manner for the effective treatment of CVOs. The Traversa is an enabling technology which will disrupt the market by democratizing physician access to the treatment of CVOs. The innovation has a significantly different approach compared to existing solutions on the market or that are currently in development. All other solutions are either off-label tools that have a high risk of perforation, or standard crossing tools with no specific indication or features for venous recanalization. Physicians use them as workarounds when the procedure fails with standard guidewires. In contrast, Traversa is the first tool designed specifically for crossing CVOs, allowing for an unparalleled level of control that will enable interventional radiologists and vascular surgeons to cross occlusions every time. VeinWay was created as part of the entrepreneur in residence program with the MEDX Xelerator, which supports and helps inventors and entrepreneurs cultivate early-stage ideas addressing complex unmet clinical needs.

Cumulative Funding Raised Over Time ($)

Latest News

May 28, 2024 · venousnews.com

growth-positive

VeinWay CEO: “This is a pivotal year for us” - Venous News

VeinWay, a medical device company specializing in venous disease, is planning to start a 30-patient trial to support FDA clearance and initial commercialization efforts by the end of 2024. The company has already successfully performed seven compassionate-use cases with its Traversa device, a tool for crossing tough venous occlusions. CEO Jordan Pollack anticipates challenges in fundraising but also sees a lot of interest from major strategic players. He envisions VeinWay becoming a prominent company in the venous space, filling a gap left by larger companies focusing on arterial disease.

InvestmentExpand

Sep 7, 2023 · www.medxelerator.com

Growth-Positive

VeinWay Closes Oversubscribed SAFE Round and Begins Series A Round

VeinWay, a medical device company, has successfully closed an oversubscribed SAFE round of investment and has opened a series A round. The funds will be used to complete design verification testing and to prepare for VeinWay’s First-in-Human clinical trial of its Traversa system towards an FDA IDE trial planned for the first half of 2024. The company also announced that Stephen Black, MD and Houman Jalaie, MD, PhD have joined the company’s scientific advisory board.

InvestmentManagement Changes

May 23, 2023 · www.calcalistech.com

growth-positive

VeinWay opens up the path to stop blood clots in underappreciated patients | CTech

VeinWay Ltd., a company focused on improving access to healthcare for patients with chronic venous disease, has raised $2.5 million in its latest investment round. The company is developing a novel catheter called Traversa, which is designed to safely and efficiently cross chronic blockages in veins. The Traversa device aims to significantly shorten procedure time and improve outcomes for patients. VeinWays CEO, Jordan Pollack, and CTO, Ben Friesem, bring extensive experience in medical device design and engineering to the company. The market for venous chronic total occlusion (CTO) devices is emerging, and VeinWay aims to jumpstart the market with its dedicated crossing tool. The companys main customers are interventional radiologists and vascular surgeons. Traversa has been used in clinical cases and will undergo a formal clinical trial starting in October 2023. VeinWay plans to seek FDA and EU MDR approval in late 2024 and 2025, respectively.

Investment

Mar 1, 2022 · medium.com

growth-positive

Health Tech: Jordan Pollack on How VeinWay's Technology Can Make an Important Impact on Our Overall...

The article is an interview with Jordan Pollack, the CEO of VeinWay, a medical technology company that is part of the MEDX Xelerator portfolio. Pollack discusses his career journey, the challenges he faced, and the inspiration behind VeinWay. The company is developing a device to treat Chronic Venous Occlusions (CVOs), a condition that affects almost 20% of people worldwide. The device, called Traversa, is designed to recanalize chronic venous occlusions quickly, safely, and efficiently. Pollack believes that the device will democratize chronic DVT/PTS treatment and improve the quality of life for patients.

Management ChangesExpand

Nov 23, 2021 · www.medxelerator.com

growth-positive

MEDX Xelerator Invests In Three New Health Technology Ventures

MEDX Xelerator has founded three new start-up companies as part of its technology development program. The companies will receive financing and support services to expedite their technology development. The three companies are VeinWay, EyeMed, and BeWeld, which focus on treating chronic venous blockages, premium lenses for intraocular implantation, and automating the manufacturing processes of implantable devices, respectively. MEDX Xelerator collaborates with hospitals and multinational companies to identify and address unmet clinical needs through innovation. The incubator has achieved significant milestones, including collaborations with CBG and West Pharmaceutical Services, and the establishment of a program for cardiovascular medical device entrepreneurs seeking financing. MEDX Xelerator is a leading international medical device and digital health-focused incubator founded in 2016 and operates under the Israel Innovation Authority.

PartnersInvestment

Funding

Team Members

2

Employees: 1-10

Web & Social Links

Locations

Ariel Sharon Boulevard 8, Or Yehuda, Israel

Photos & Videos

2 item(s)

VeinWay Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info